AstraZeneca (AZN)

Executive Summary

AstraZeneca (AZN) is a global biopharmaceutical leader with a market cap exceeding $285B, driven by a robust pipeline of 197 projects and 16 blockbuster medicines across oncology, cardiovascular/renal/metabolic, respiratory/immunology, vaccines, and rare diseases. The company's core strength lies in its oncology franchise, anchored by Tagrisso, Imfinzi, and Lynparza, alongside next-generation antibody-drug conjugates (ADCs) like Enhertu and Datopotamab deruxtecan (Dato-DXd). Recent catalysts include FDA approvals for Calquence in CLL and Enhertu in HER2-low breast cancer, while ongoing trials in earlier-stage settings and novel modalities (e.g., bispecifics, cell therapy) support long-term growth. With a strong balance sheet and consistent R&D investment, AstraZeneca is well-positioned to sustain mid-single-digit revenue growth through 2030, though pipeline execution and patent expiries remain key risks.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on Datopotamab deruxtecan (Dato-DXd) for HR+/HER2- metastatic breast cancer75% success
• H2 2026Phase 3 DESTINY-Breast09 readout for Enhertu in first-line HER2+ metastatic breast cancer85% success
• Q3 2026FDA decision on Calquence (acalabrutinib) for first-line mantle cell lymphoma70% success